ARMED: an Australian cohort retrospective observational study to understand motivations for switching and clinical outcomes of individuals switching to dolutegravir/lamivudine

Daniela Eassey, Jason J. Ong, Ken Koh, David Nolan, David Baker, Mark O’Reilly, Beng Eu, Jillian Lau, Fiona Bisshop, Jessica Kent, Andrés Doblado-Maldonado, Daniel Cowley, Mark Bloch

Open source

DOI
10.1071/sh26036
Published
2026-08-20
Container
Sexual Health
Publisher
CSIRO Publishing
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1071/sh26036,
  title = {ARMED: an Australian cohort retrospective observational study to understand motivations for switching and clinical outcomes of individuals switching to dolutegravir/lamivudine},
  author = {Daniela Eassey and Jason J. Ong and Ken Koh and David Nolan and David Baker and Mark O’Reilly and Beng Eu and Jillian Lau and Fiona Bisshop and Jessica Kent and Andrés Doblado-Maldonado and Daniel Cowley and Mark Bloch},
  year = {2026},
  journal = {Sexual Health},
  doi = {10.1071/sh26036},
  url = {https://doi.org/10.1071/sh26036}
}

RIS

TY  - JOUR
TI  - ARMED: an Australian cohort retrospective observational study to understand motivations for switching and clinical outcomes of individuals switching to dolutegravir/lamivudine
AU  - Daniela Eassey
AU  - Jason J. Ong
AU  - Ken Koh
AU  - David Nolan
AU  - David Baker
AU  - Mark O’Reilly
AU  - Beng Eu
AU  - Jillian Lau
AU  - Fiona Bisshop
AU  - Jessica Kent
AU  - Andrés Doblado-Maldonado
AU  - Daniel Cowley
AU  - Mark Bloch
PY  - 2026
JO  - Sexual Health
DO  - 10.1071/sh26036
UR  - https://doi.org/10.1071/sh26036
ER  - 

APA

Eassey, D., Ong, J. J., Koh, K., Nolan, D., Baker, D., O’Reilly, M., Eu, B., Lau, J., Bisshop, F., Kent, J., Doblado-Maldonado, A., Cowley, D., & Bloch, M. (2026). ARMED: an Australian cohort retrospective observational study to understand motivations for switching and clinical outcomes of individuals switching to dolutegravir/lamivudine. Sexual Health. https://doi.org/10.1071/sh26036

Source records